TB-500 is a synthetic version of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino acid peptide found in virtually every human and animal cell. It is widely studied for its powerful role in tissue repair, cell migration, and recovery from injury.
Thymosin Beta-4 was first isolated from the thymus gland in the 1960s. Since then, decades of research have revealed its critical function in wound healing and inflammation control, leading to the development of TB-500 as a targeted therapeutic peptide.
TB-500 works by upregulating actin, a protein essential for cell structure and movement. This allows cells to migrate faster toward injury sites, accelerating the body's natural repair mechanisms for soft tissue, blood vessels, and even cardiac muscle.
Unlike many peptides that only act locally, TB-500 has a unique molecular structure that enables systemic effects. This means it can promote healing throughout the entire body regardless of where it is injected, making dosing convenient and flexible.
For educational and research purposes only. Never use any peptide or substance based on information found here — always consult a licensed healthcare professional before making any medical or health-related decision.
No reviews yet. Be the first.
Thymosin Beta-4 has been extensively studied in both preclinical and clinical settings. A landmark study published in the Annals of the New York Academy of Sciences (2007) demonstrated Tβ4's ability to promote cardiomyocyte survival and improve cardiac function following induced myocardial infarction in mice, with treated subjects showing 50% smaller infarct sizes. Research published in Wound Repair and Regeneration (2012) showed topical Tβ4 accelerated wound healing in human diabetic patients, with 25% faster closure rates compared to standard care. A 2014 study in the International Journal of Molecular Sciences confirmed TB-500's anti-inflammatory effects through suppression of NF-κB pathways and reduction of pro-inflammatory cytokines. In equine studies, TB-500 has been widely used for racehorse injury recovery, with veterinary reports indicating significantly reduced recovery times from tendon injuries. Phase II clinical trials for Tβ4 in epidermolysis bullosa and dry eye syndrome have shown promising results, with favorable safety profiles. The peptide appears well-tolerated in human studies, though more research is needed on long-term effects and optimal dosing for various conditions.